V-ATPase as a mediator of treatment resistance in Glioblastoma Multiforme: an in vitro study to investigate new therapeutic strategies

Authors

  • Eleonora Messuti University of Milano-Bicocca, School of Medicine and Surgery, Monza
  • Martina Giambra University of Milano-Bicocca, School of Medicine and Surgery, Monza
  • Serena Redaelli University of Milano-Bicocca, School of Medicine and Surgery, Monza
  • Andrea Di Cristofori San Gerardo Hospital, ASST Monza, Neurosurgery Unit, Monza
  • Carlo Giussani San Gerardo Hospital, ASST Monza, Neurosurgery Unit, Monza
  • Angela Bentivegna University of Milano-Bicocca, School of Medicine and Surgery, Monza

DOI:

https://doi.org/10.4081/bse.182

Keywords:

GBM, GSC, V-ATPase, Baf-A1

Abstract

Recent evidences suggest the involvement of the Vacuolar H+ ATPase (V-ATPase) in the development and/or progression of Glioblastoma Multiforme (GBM). This proton pump could be a valid therapeutic target but more in-depth studies are necessary. The aim of this study is to better define the in vitro effects on Glioma Stem Cell (GSC) primary cultures viability of single and combined treatment with Bafilomycin-A1 (Baf-A1), a V-ATPase inhibitor, and Temozolomide (TMZ), the chemotherapeutic agent currently used to treat GBM patients. We found out that GSC were resistant to TMZ and more sensitive to treatments with Baf-A1 and that the two drugs exerted a synergistic effect when administered together.

Downloads

Download data is not yet available.

References

Downloads

Published

29-09-2021

Issue

Vol. 2 No. 1 (2021)

Section

Communications

License

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

How to Cite

V-ATPase as a mediator of treatment resistance in Glioblastoma Multiforme: an in vitro study to investigate new therapeutic strategies. (2021). Biomedical Science and Engineering, 2(1). https://doi.org/10.4081/bse.182